Lirilumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | KIR2DL1/2/3 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6452H9918N1698O2030S46 |
Molar mass | 145228.93 g·mol−1 |
Lirilumab (
INN) is a human monoclonal antibody designed for the treatment of cancer.[1][2] It binds to KIR2DL1/2L3.[3]
This drug was developed by Innate Pharma and is licensed to
Bristol-Myers Squibb
.
Clinical trials
A phase 2 clinical trial for acute myeloid leukemia (AML)[4] was terminated early ("failed") in 2017.[5]
It was registered for a trial for
As of November 2017[update] nine clinical trials of lirilumab are registered as active.[8]
References
- ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lirilumab, American Medical Association.
- PMID 19553639.
- ^ Clinical trial number NCT01687387 for "Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)" at ClinicalTrials.gov
- ^ Innate Pharma Leukemia Candidate Lirilumab Fails Phase II Trial. Feb 2017
- ^ Clinical trial number NCT03341936 for "Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck " at ClinicalTrials.gov
- ^ Bad news for Innate Pharma as BMS-backed drug stumbles nov 2017
- ^ lirilumab trials